



(86) **Date de dépôt PCT/PCT Filing Date:** 2013/07/19
 (87) **Date publication PCT/PCT Publication Date:** 2014/01/23
 (85) **Entrée phase nationale/National Entry:** 2015/01/16
 (86) **N° demande PCT/PCT Application No.:** US 2013/051263
 (87) **N° publication PCT/PCT Publication No.:** 2014/015247
 (30) **Priorités/Priorities:** 2012/07/19 (US61/673,514);
 2013/03/15 (US61/793,929)


(51) **Cl.Int./Int.Cl. C07D 403/12** (2006.01),
A61K 31/4015 (2006.01), **A61K 31/4025** (2006.01),
A61P 17/14 (2006.01), **A61P 19/10** (2006.01),
A61P 25/02 (2006.01), **A61P 27/02** (2006.01),
A61P 27/06 (2006.01), **C07D 207/20** (2006.01)

(71) **Demandeur/Applicant:**
 CAYMAN CHEMICAL COMPANY, INC., US

(72) **Inventeurs/Inventors:**
 BARRETT, STEPHEN DOUGLAS, US;
 CISKE, FRED LAWRENCE, US;
 COLOMBO, JOSEPH MICHAEL, US;
 ENDRES, GREGORY WILLIAM, US;
 GERMAIN, BRADLEE DAVID, US; ...

(54) **Titre : COMPOSES DE DIFLUOROLACTAME COMME AGONISTES SELECTIFS DU RECEPTEUR EP4, DESTINES A ETRE
 UTILISES DANS LE TRAITEMENT DE MALADIES ET D'AFFECTIONS MEDIEES PAR EP4**

(54) **Title: DIFLUOROLACTAM COMPOUNDS AS EP₄ RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-
 MEDIATED DISEASES AND CONDITIONS**



(57) **Abrégé/Abstract:**

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L¹, L², L⁴, R¹, R⁴, R⁵, R⁶, and s are as defined in the specification. Compounds of formula (I) are EP₄ agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

(72) **Inventeurs(suite)/Inventors(continued):** KORNILOV, ANDRIY, US; KRAMER, JAMES BERNARD, US;
UZIEBLO, ADAM, US; MAXEY, KIRK M., US

(74) **Agent:** CASSAN MACLEAN